Cervical cancer has emerged as the “fastest-rising form of cancer” in Canada, prompting urgent calls from healthcare professionals for government intervention. At a press conference held in Ottawa by the Society of Gynecologic Oncology of Canada, experts labelled the situation a “silent national health crisis”. This plea comes despite the Canadian government’s commitment, outlined in a July 2025 action plan, to eradicate cervical cancer as a public health issue by 2040.
Alarming Statistics Highlight Urgency
Dr. Shannon Salvador, the president of the Society of Gynecologic Oncology of Canada, highlighted the disturbing reality: in 2025, approximately 1,650 Canadians will be diagnosed with cervical cancer, with an estimated 430 fatalities resulting from the illness—deaths that could potentially be prevented.
“While we celebrate advancements in modern medicine, we must acknowledge an alarming outlier,” Dr. Salvador stated. Despite the availability of effective screening and vaccination methods, Canada is struggling with stagnant human papillomavirus (HPV) vaccination rates, which currently hover at just 64 per cent. This figure falls significantly short of the targets necessary for eliminating cervical cancer.
“This statistic is not merely a reflection of medical shortcomings; it signifies a failure in policy,” Dr. Salvador added, emphasising the need for a more proactive approach.
A Shift in Screening Practices
The Society of Gynecologic Oncology is now advocating for an immediate overhaul of cervical cancer screening methods, proposing the implementation of HPV DNA testing as a standard practice. They urge the introduction of self-collection kits to facilitate easier screening access, particularly for those who may face barriers such as geographical isolation or lack of healthcare resources.
Currently, HPV testing typically involves a swab to collect cells from the cervix or vagina. The Canadian Cancer Society has stated that self-administered testing is an option, allowing individuals to collect samples from home. This method could significantly reduce the obstacles faced by many, especially in rural, Indigenous, and underserved communities, who often “fall through the cracks” of an already fragmented healthcare system.
Addressing Inequities in Healthcare
Dr. Sarah Kean, the provincial lead for cervical cancer in Manitoba, underscored the disparities faced by Indigenous women, who are diagnosed at higher rates and often present with more advanced stages of the disease. “These outcomes are not due to biology,” she asserted, but rather reflect systemic issues including lack of access to screenings, geographic barriers, and historical injustices rooted in colonial practices.
Dr. Kean advocates for a “robust and accessible HPV screening programme” across Canada, emphasising that merely updating guidelines is inadequate. She calls for universal access to primary HPV testing, supported by clear national standards, to address the pressing need for comprehensive healthcare access.
The Financial Burden of Inaction
The financial implications of cervical cancer are significant. In 2024, the costs associated with treating cervical cancer in Canada amounted to approximately £132 million. Screening eligible Canadians for cervical cancer would incur an estimated £106 million over a five-year period. These figures highlight not only the human cost of the disease but also the economic burden on the healthcare system.
Why it Matters
The rising incidence of cervical cancer in Canada signals a critical moment for intervention. As the government strives to meet its 2040 elimination goal, the call for updated policies and improved access to healthcare resources is more crucial than ever. Addressing these challenges is not only an ethical imperative but a necessary step towards safeguarding the health of vulnerable populations and ensuring equitable access to preventative care across the nation. The lives of thousands depend on decisive action today.
